Delaying Diabetes

Langreth, Robert
February 2008
Forbes Asia;2/11/2008, Vol. 4 Issue 3, p71
The article focuses on anti-CD3 antibody, a drug that aims to delay or prevent development of the type 1 diabetes by arresting the immune system's attack on pancreatic islet cells. The drugs, now entering final-stage human trials, are given to recently diagnosed patients for just a few days or weeks but appear to preserve some insulin-producing capacity for years. Ultimately the drugs may even be able to prevent the disease from striking people at high risk because of a family history of diabetes or bad genes.


Related Articles

  • Pancreatic islet cell tumor mimicking obstructive chronic pancreatitis: a case report. Wang, Xiaohong I.; Thomas MD, Jaiyeola; Adegboyega, Patrick; Zhang, Songlin // Internet Journal of Pathology;2010, Vol. 10 Issue 2, p7 

    Context: Pancreatic islet cell tumors are uncommon lesions, and nonfunctional islet cell tumors presenting with pancreatitis are extremely rare. Many patients with pancreatitis and islet cell tumors may initially present with acute attacks, which sometimes recur and the diagnosis of the tumors...

  • In vivo derivation of glucose-competent pancreatic endocrine cells from bone marrow without evidence of cell fusion. Ianus, Andreea; Holz, George G.; Theise, Neil D.; Hussain, Mehboob A. // Journal of Clinical Investigation;3/15/2003, Vol. 111 Issue 6, p843 

    Presents information on a study which demonstrated that bone marrow-derived cells populate pancreatic islets of Langerhans. Methodologies of the study; Results of the study; Discussion on the study.

  • Xenotransplantation's benefits outweigh risks. Valdes Gonzalez, Rafael // Nature;11/21/2002, Vol. 420 Issue 6913, p268 

    Responds to comments about clinical trials of pancreatic islet xenotransplantation in Mexico. Existence of a general health law that regulates the conduct of all experimental investigations; Absence of an appropriate model for auto-immune diabetes in non-human primates.

  • Influence of the purification of human adult pancreatic islets on insulin secretion. Nikolic, Dragan M.; Djordjevic, Predrag B.; Dimitrijevic-Sreckovic, Vesna; D�ingala�evic, Marina; Belrf, Sandra; Kalezic, Nevena // Vojnosanitetski Pregled: Military Medical & Pharmaceutical Journ;Feb2010, Vol. 67 Issue 2, p128 

    Background/Aim. The most effective method for human adult pancreatic islets purification is density-gradient centrifugation. The aim of this study was to analyze the effects of non-automated purification on preservation of functional capacity of human adult pancreatic islet cells. Methods. Human...

  • Quantitative analysis of cell composition and purity of human pancreatic islet preparations. Pisania, Anna; Weir, Gordon C.; O'Neil, John J.; Omer, Abdulkadir; Tchipashvili, Vaja; Ji Lei; Colton, Clark K.; Bonner-Weir, Susan // Laboratory Investigation (00236837);Nov2010, Vol. 90 Issue 11, p1661 

    Despite improvements in outcomes for human islet transplantation, characterization of islet preparations remains poorly defined. This study used both light microscopy (LM) and electron microscopy (EM) to characterize 33 islet preparations used for clinical transplants. EM allowed an accurate...

  • Matrix metalloproteinases 2 and 9 are dispensable for pancreatic islet formation and function in vivo. Perez, Sabina E.; Cano, David A.; Dao-Pick, Trang; Rougier, Jean-Phillipe; Werb, Zena; Hebrok, Matthias // Diabetes;Mar2005, Vol. 54 Issue 3, p694 

    Pancreatic islet formation is a highly regulated process that is initiated at the end of gestation in rodents. Endocrine precursor cells first form within the epithelium of duct-like structures and then delaminate from the epithelium, migrate, and cluster during the early stages of islet...

  • Where Do We Stand With INGAP? Vinik, Aaron I. // Diabetes Health;Jun2004, Vol. 13 Issue 6, p72 

    Interviews physician Aaron I. Vinik, research director for the Strelitz Diabetes Institutes at Eastern Virginia Medical School and one of the discoverer of the islet neogenesis associated protein (INGAP). Significance of the phase 2 trials; Results obtained in phase 1B; Role of INGAP in insulin...

  • Microencapsulated Pancreatic Islet Allografts Into Nonimmunosuppressed Patients With Type 1 Diabetes. Calafiore, Riccardo; Basta, Giuseppe; Luca, Giovanni; Lemmi, Angelo; Montanucci, M. Pia; Calabrese, Giuseppe; Racanicchi, Leda; Mancuso, Francesca; Brunetti, Paolo // Diabetes Care;Jan2006, Vol. 29 Issue 1, p137 

    The article presents information on a phase 1 pilot clinical trial of microencapsulated pancreatic islet allograft into 10 nonimmunsuppressed patients with type 1 diabetes, under permission and surveillance by the Italian Ministry of Health. Research design and methods are given. Results and...

  • Sernova Breaks New Ground In Islet Cell Transplantation. Shaffer, Catherine // BioWorld Today;8/17/2012, Vol. 23 Issue 160, p1 

    The article reports on the Phase I/II trial conducted by Sernova Corp. involving patients with type I diabetes which combines transplanted insulin-producing islet cells with its Cell Pouch device. A total of 5 million dollars has been raised by the company to finance the test which is expected...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics